

Linda M Henricks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7248586/publications.pdf>

Version: 2024-02-01

23
papers

1,732
citations

516710

16
h-index

677142

22
g-index

23
all docs

23
docs citations

23
times ranked

1778
citing authors

#	ARTICLE	IF	CITATIONS
1	Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 62-68.	4.7	32
2	Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 591-604.	4.7	37
3	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? – Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e67.	10.7	2
4	A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019, 107, 60-67.	2.8	65
5	Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the <i>DPYD</i> *2A variant: A matched pair analysis. <i>International Journal of Cancer</i> , 2019, 144, 2347-2354.	5.1	40
6	Capecitabine-based treatment of a patient with a novel <i>DPYD</i> genotype and complete dihydropyrimidine dehydrogenase deficiency. <i>International Journal of Cancer</i> , 2018, 142, 424-430.	5.1	15
7	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 210-216.	4.7	407
8	Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. <i>Genes</i> , 2018, 9, 585.	2.4	10
9	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , 2018, 104, 210-218.	2.8	14
10	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology</i> , The, 2018, 19, 1459-1467.	10.7	238
11	Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2761-2769.	2.4	26
12	Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. <i>British Journal of Cancer</i> , 2017, 116, 1415-1424.	6.4	94
13	Letter regarding Zhao et al. entitled “ <i>DPYD</i> gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia”. <i>Tumor Biology</i> , 2017, 39, 101042831770162.	1.8	0
14	DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. <i>Annals of Oncology</i> , 2017, 28, 2915-2922.	1.2	59
15	Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	3.0	8
16	Rs895819 in <i>MIR27A</i> improves the predictive value of <i>DPYD</i> variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. <i>International Journal of Cancer</i> , 2016, 138, 2752-2761.	5.1	28
17	Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 126, 75-82.	2.8	39
18	Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 875-880.	2.3	17

#	ARTICLE	IF	CITATIONS
19	Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2016, 54, 40-48.	2.8	110
20	RasGRP1 opposes proliferative EGFRâ€“SOS1â€“Ras signals and restricts intestinal epithelial cell growth. <i>Nature Cell Biology</i> , 2015, 17, 804-815.	10.3	54
21	The use of combinations of monoclonal antibodies in clinical oncology. <i>Cancer Treatment Reviews</i> , 2015, 41, 859-867.	7.7	79
22	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2015, 16, 1639-1650.	10.7	277
23	Translating <i>DPYD</i> genotype into DPD phenotype: using the <i>DPYD</i> gene activity score. <i>Pharmacogenomics</i> , 2015, 16, 1275-1284.	1.3	81